| Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. | |
| | |
MedLine Citation:
|
PMID: 23162092 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONTEXT: The current survey study investigated the recurrence rate of hyperprolactinemia after cabergoline (CAB)-induced pregnancy and after lactation as well as safety of CAB exposure during early gestation. PATIENTS AND METHODS: From 1997-2008, 143 pregnancies were recorded in 91 patients with hyperprolactinemia (age 30.4 ± 4.7 yr, 76 microadenomas, 10 macroadenomas, and five nontumoral hyperprolactinemia). CAB therapy was discontinued within wk 6 of gestation in all. Pregnancies were monitored until delivery or termination, during and after lactation, twice yearly up to 60 months. The incidence of abortions, premature delivery, and fetal malformations was also analyzed. RESULTS: Pregnancies resulted in 13 (9.1%) spontaneous abortions and 126 (88.1%) live births. No neonatal malformations and/or abnormalities were recorded. In 29 of 91 patients (three with macroadenomas), treatment with CAB had to be restarted within 6 months after lactation because of hyperprolactinemia recurrence, whereas in 68% of cases, no additional therapy was required up to 60 months. No tumor mass enlargement was observed. All patients but three were breastfeeding, 35 (38.5%) for less than 2 months and 56 (61.5%) for 2-6 months. Three months after cessation of lactation and 60 months after pregnancy, no difference in prolactin levels was found between patients nursing for less than 2 months and 2-6 months. CONCLUSIONS: Fetal exposure to CAB at conception does not induce any increased risk of miscarriage or malformations. Pregnancy is associated with normalization of prolactin levels in 68% of patients. Breastfeeding does not increase the recurrence rate of hyperprolactinemia. |
| | |
Authors:
|
Renata S Auriemma; Ylenia Perone; Antonella Di Sarno; Ludovica F S Grasso; Ermelinda Guerra; Maurizio Gasperi; Rosario Pivonello; Annamaria Colao |
Publication Detail:
|
Type: Evaluation Studies; Journal Article Date: 2012-11-16 |
Journal Detail:
|
Title: The Journal of clinical endocrinology and metabolism Volume: 98 ISSN: 1945-7197 ISO Abbreviation: J. Clin. Endocrinol. Metab. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-01-07 Completed Date: 2013-03-07 Revised Date: 2013-05-28 |
Medline Journal Info:
|
Nlm Unique ID: 0375362 Medline TA: J Clin Endocrinol Metab Country: United States |
Other Details:
|
Languages: eng Pagination: 372-9 Citation Subset: AIM; IM |
Affiliation:
|
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, via S. Pansini 5, I-80131 Napoli, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antineoplastic Agents / adverse effects, therapeutic use Breast Feeding Data Collection Dopamine Agonists / adverse effects, therapeutic use Ergolines / adverse effects, therapeutic use Female Humans Hyperprolactinemia / complications, drug therapy, epidemiology*, etiology Infertility, Female / drug therapy, epidemiology, etiology Lactation* / blood, physiology Observation Pituitary Neoplasms / complications, drug therapy, epidemiology Pregnancy Pregnancy Complications, Neoplastic / drug therapy, epidemiology, etiology Pregnancy Outcome / epidemiology Prolactinoma / complications, drug therapy, epidemiology Puerperal Disorders / epidemiology*, etiology Recurrence Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Dopamine Agonists; 0/Ergolines; LL60K9J05T/cabergoline |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5?-Reductase, Explaining the N...
Next Document: Inverse Relationship between Serum Osteocalcin Levels and Visceral Fat Area in Chinese Men.